The Board of Directors of PharmaCyte Biotech, Inc. has authorized a buyback plan on September 27, 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.75 GBX | -5.17% | -6.78% | -5.17% |
05-13 | EARNINGS AND TRADING: itim loss narrows; Vela trims EnSilica stake | AN |
05-13 | Earnings Flash (HUD.L) HUDDLED GROUP Posts FY23 Revenue GBP2.4M | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-5.17% | 11.87M | |
+2.33% | 208B | |
+3.96% | 195B | |
+37.61% | 94.4B | |
+8.68% | 86.59B | |
-25.30% | 74.99B | |
+7.61% | 50.74B | |
+27.50% | 10.89B | |
-10.14% | 8.66B | |
-22.84% | 5.11B |
- Stock Market
- Equities
- HUD Stock
- News Huddled Group Plc
- PharmaCyte Biotech, Inc. authorizes a Buyback Plan.